Somatostatin Isoproterenol Assay
Somatostatin Isoproterenol Assay - Related Videos
05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
0 Views •
Cited by 17 •
2019
The chronic administration of isoproterenol via an implanted osmotic pump has been used widely to mimic advanced heart failure in mice. Here, we describe detailed methods in surgical mini-pump implantation for the continuous isoproterenol administration over 3 weeks, as well as, echocardiographic assessment for the successful model creation.
05:31
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
0 Views •
Cited by 7 •
2012
A real-time screening procedure for identifying drugs that interact with G protein-gated inward rectifier K+ (GIRK) channels is described. The assay utilizes membrane potential-sensitive fluorescent dyes to measure GIRK channel activity. This technique is adaptable for use on a number of cell lines.
08:08
Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
0 Views •
Cited by 8 •
2013
A structured protocol is presented for a cell-based assay as a functional test to predict the prognosis of idiopathic scoliosis using cellular dielectric spectroscopy (CDS). The assay can be performed with fresh or frozen peripheral blood mononuclear cells (PBMCs) and the procedure is completed within 4 days.
08:12
The TUNEL Assay
0 Views •
2023
One of the hallmarks of apoptosis is the nuclear DNA fragmentation by nucleases. These enzymes are activated by caspases, the family of proteins that execute the cell death program. TUNEL assay is a method that takes advantage of this feature to detect apoptotic cells. In this assay, an enzyme called terminal deoxynucleotidyl transferase catalyzes the addition of dUTP nucleotides to the free 3’ ends of fragmented DNA. By using dUTPs that are labeled with chemical tags that can produce...
09:12
Aortic Ring Assay
0 Views •
Cited by 42 •
2009
Angiogenesis, the sprouting of blood vessels from pre-existing vasculature, is associated with both natural and pathological processes. Here we demonstrate an aortic ring assay that allows angiogenic potentiators and inhibitors to be directly added to aortic rings in culture. Sprouting and neovessel outgrowth can be determined by inspecting the aortic rings over a period of 6-12 days.
FAQs
The isoproterenol control defines the hormone-secretion response produced by adrenergic stimulation without somatostatin. Comparing treated samples with this reference helps distinguish direct suppression by somatostatin from the baseline secretory response. It also provides the basis for quantifying inhibitory activity, allowing somatostatin potency to be assessed under the same pancreatic experimental conditions.
Somatostatin reduces secretion after engaging receptors on pancreatic tissue or isolated islet cells. This receptor-mediated step counteracts the stimulatory signaling initiated by isoproterenol, producing a measurable decline in hormone release. The size of that decline reflects how effectively somatostatin regulates secretion and helps researchers examine inhibitory control within pancreatic endocrine systems.
Because isoproterenol stimulates insulin release while somatostatin suppresses that response, the assay models opposing regulatory influences within pancreatic endocrine tissue. Measuring the resulting secretion shows how an inhibitory pancreatic signal modifies a stimulated secretory state. This makes the system useful for examining coordinated islet regulation rather than observing somatostatin activity in isolation.
A typical workflow uses pancreatic tissue or isolated islet cells, exposes them to isoproterenol to establish stimulated secretion, and compares that response with samples receiving added somatostatin. Hormone release is then quantified relative to the isoproterenol control. The comparison provides an experimental measure of somatostatin activity under the selected cellular or tissue conditions.
Potency is evaluated from the extent to which somatostatin lowers the isoproterenol-stimulated secretion response. A stronger inhibitory effect indicates greater activity under the assay conditions, provided the result is interpreted against the corresponding isoproterenol control. This relative measurement supports characterization of somatostatin effects without treating unstimulated secretion as the primary reference.
The assay is relevant when researchers need to investigate insulin regulation, pancreatic islet function, or abnormal somatostatin signaling. By linking adrenergic stimulation with receptor-mediated inhibition, it provides a controlled way to study endocrine responses associated with these conditions. Its findings can help characterize regulatory disturbances rather than serving as a standalone clinical diagnosis.